News
ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche
Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo
